TAG’s 2026 Pipeline Report: TB Long-Acting Technologies
13 November 2026
Treatment Action Group (TAG) released its inaugural TB Long-Acting Technologies Pipeline Report.
TB is curable — yet the treatment can be punishing. People with TB often take multiple medications daily for several months. Even preventing TB means weeks of pills, taken by people who exhibit no symptoms. The physiological and psychological burden of managing a high volume of daily medication over an extended period can make it harder to finish treatment.
Long-acting technologies (LATs) could change that. Most current LATs for TB under development are injectables — one shot releases medicine slowly over weeks or months, replacing days of pills. Even a single long-acting component in a regimen could cut pill burden, and a single shot for preventive treatment opens the possibility of a pill-free preventative regimen.
The field is still in a nascent stage, with only two long-acting products for TB in clinical trials while several are being tested in animals. But this moment merits recognition because of the possibility it offers. The TB Long-Acting Technologies Pipeline Report shows the next stage of TB science taking shape, and a commitment to making life easier for people with TB.
Inside the report:
- A young pipeline. 13 long-acting products are in development. Two are in trials: Johnson & Johnson’s long-acting bedaquiline, and Akagera’s AKG-100, a novel compound administered via IV that reported positive early results in July 2026.
- Early signs on safety. Long-acting bedaquiline finished a first safety trial with no new or unique safety concerns from the long-acting formulation. A phase III trial of a single shot for TB preventive treatment is in development targeting a 2028 launch.
- Hard questions. Replacing every pill would take long-acting versions of every drug in a regimen, and unlike pills, injections can’t be stopped once given. Past TB injectables, which caused hearing loss, cast a long shadow over new long-acting injectables and individuals will want a choice in the treatment option for them.
Because these products are years away, people affected by TB can still shape them, from community advisory boards to early inclusion of pregnant people and children. With existing drugs and novel compounds both being tested for long-acting formulations, the goal is clear — the hardest part of being treated for TB should not be the treatment.
Source: Treatment Action Group
